Cerebral Palsy Research Program Authorization Act
Turning Recognition into Responsibility: The Push for H.R. 2178
The Moment: Recognition on the House Floor
When Representative George Latimer honored Dr. Kathleen Friel on the House floor, it was more than a formal gesture—it was a rare moment of visibility for the adult cerebral palsy community. Dr. Friel, a neuroscientist living with CP, embodies the brilliance and purpose that define our community. However, as we celebrate this recognition, we must also address the “harder truth”: Recognition is the spark, but policy is the engine.
The Reality: Why has H.R. 2178 stalled?
The Cerebral Palsy Research Program Authorization Act has been introduced in the three most recent Congressional sessions. Despite affecting over a million Americans, it has yet to cross the finish line. We often hear the question: Why the reluctance?
The barriers are rarely about the merit of the bill, but rather systemic hurdles:
The “Pediatric Lens”: For decades, CP has been framed exclusively as a childhood condition. Many in Congress do not yet realize that CP is a lifelong journey, requiring dedicated research into adult health outcomes, aging, and secondary conditions.
Funding Competition: Without a dedicated federal “line item,” CP research is often forced to compete within broader, non-specific categories at the CDC and NIH. H.R. 2178 would change this by establishing a specific $5 million authorization.
Lack of Data: Because there is no national surveillance system for CP across the lifespan, it is difficult to provide the “hard numbers” that many legislators demand before committing to long-term funding.
